Diagnostic Accuracy of Serum Procalcitonin (PCT) as an Early Biomarker of Neonatal Sepsis using Blood Culture as Gold Standard: A Prospective Study
DOI:
https://doi.org/10.63682/jns.v13i1.8426Keywords:
Neonatal sepsis, Procalcitonin, Blood culture, Diagnostic accuracy, Early biomarker, ROC curveAbstract
Background: Although neonatal sepsis can be identified and treated early, blood cultures are still the gold standard and, unfortunately, these traditional methods to diagnose sepsis in newborns stagnate progress with their lengthy processing times and delays in yielding results, leading to increased rates of morbidity and mortality. Recently, there has been a shift towards using PCT as a serum biomarker for identifying sepsis in neonates, and one of the central goals of this study is to assess the accuracy of serum PCT in comparison to blood cultures.
Methods: This was a prospective study spanning from January 2024 to September 2024 involving 61 neonates with clinical signs of sepsis. Blood samples were taken before any antibiotics were administered for PCT testing and culture. A PCT level greater than 0.5ng/mL was defined as elevated. Diagnostic accuracy parameters (sensitivity, specificity, predictive values, and area under the ROC curve) were calculated.
Results: Out of 61 neonates, 25 (41%) had positive blood cultures. Serum PCT levels were elevated in 23 of these cases. ‘The sensitivity and specificity of PCT were 92.0% and 83.3%, respectively’. ‘The negative predictive value was 93.8%, and the area under the ROC curve was 0.927, indicating high diagnostic performance’.
Conclusion: Serum PCT is a reliable and effective early biomarker for neonatal sepsis. Its high sensitivity and negative predictive value make it particularly useful in ruling out infection, thus supporting timely and targeted clinical decision-making.
Downloads
Metrics
References
Habib, A., et al., Diagnostic accuracy of serum procalcitonin (pct) as an early biomarker of neonatal sepsis using blood culture as gold standard. J Coll Physicians Surg Pak, 2021. 30(4): p. 383-387.
Liu, C., C. Fang, and L. Xie, Diagnostic utility of procalcitonin as a biomarker for late-onset neonatal sepsis. Translational Pediatrics, 2020. 9(3): p. 237.
Go, H., et al., Diagnostic accuracy of biomarkers for early-onset neonatal bacterial infections: evaluation of serum procalcitonin reference curves. Diagnostics, 2020. 10(10): p. 839.
Taneja, R. and P. Batra, Biomarkers as point of care tests (POCT) in neonatal sepsis: A state of science review. Journal of neonatal-perinatal medicine, 2021. 14(3): p. 331-338.
Anugu, N.R. and S. Khan, Comparing the diagnostic accuracy of procalcitonin and C-reactive protein in neonatal sepsis: a systematic review. Cureus, 2021. 13(11).
Srinivasan, L., et al., Procalcitonin for the diagnosis of sepsis in neonates: a diagnostic test accuracy review. The Cochrane Database of Systematic Reviews, 2023. 2023(4): p. CD014196.
Chaurasia, S., et al., Procalcitonin for detecting culture-positive sepsis in neonates: a prospective, multicenter study. Neonatology, 2023. 120(5): p. 642-651.
van Leeuwen, L.M., et al., Diagnostic value of maternal, cord blood and neonatal biomarkers for early onset sepsis: a systematic review and meta-analysis. Clinical Microbiology and Infection, 2024.
Sakyi, S.A., et al., Individual and combined bioscore model of presepsin, procalcitonin, and high sensitive C-reactive protein as biomarkers for early diagnosis of paediatric sepsis. Heliyon, 2020. 6(9).
Beaumont, R., K. Tang, and A. Gwee, The Sensitivity and Specificity of Procalcitonin in Diagnosing Bacterial Sepsis in Neonates. Hospital Pediatrics, 2024. 14(3): p. 199-208.
Meena, C.L., et al., Diagnostic Accuracy of Cord and Venous Blood Procalcitonin in Relation to Neonatal Sepsis Screen. Journal of Neonatology, 2022. 36(4): p. 288-297.
Liu, C., et al., Clinical values of common biomarkers for efficacy monitoring of antibiotics in early-onset neonatal sepsis. Translational Pediatrics, 2020. 9(5): p. 669.
Goyal, M., et al., Diagnostic accuracy of point-of-care testing of C-reactive protein, interleukin-6, and procalcitonin in neonates with clinically suspected sepsis: a prospective observational study. Medical Principles and Practice, 2024. 33(3): p. 291-298.
Gopal, N., et al., Advancement in biomarker based effective diagnosis of neonatal sepsis. Artificial Cells, Nanomedicine, and Biotechnology, 2023. 51(1): p. 476-490.
Celik, I.H., et al., Diagnosis of neonatal sepsis: the past, present and future. Pediatric research, 2022. 91(2): p. 337-350.
Downes, K.J., J.C. Fitzgerald, and S.L. Weiss, Utility of procalcitonin as a biomarker for sepsis in children. Journal of clinical microbiology, 2020. 58(7): p. 10.1128/jcm. 01851-19.
Hincu, M.-A., et al., Relevance of biomarkers currently in use or research for practical diagnosis approach of neonatal early-onset sepsis. Children, 2020. 7(12): p. 309.
Ahmad, S. and S. Kumar, Retrospective Analysis of C-Reactive Protein and Blood Culture in Diagnosing Neonatal Sepsis. Azerbaijan Pharmaceutical and Pharmacotherapy Journal, 2024. 23(3): p. 1-6.
Bibi, A., et al., Procalcitonin as a biomarker of bacterial infection in critically ill patients admitted with suspected Sepsis in Intensive Care Unit of a tertiary care hospital. Pakistan journal of medical sciences, 2021. 37(7): p. 1999.
Sethi, K., et al., A study on bacteriological profile in suspected cases of neonatal sepsis and its correlation with various biomarkers in the rural population of a university hospital. Journal of Family Medicine and Primary Care, 2023. 12(10): p. 2313-2317.
Yu, R., et al., Combination of 16S rRNA and procalcitonin in diagnosis of neonatal clinically suspected sepsis. Journal of International Medical Research, 2020. 48(3): p. 0300060519892418.
Narang, N., et al., Comparison of Procalcitonin With C-Reactive Protein In Early Diagnosis of Neonatal Sepsis: A Cross-sectional study. European Journal of Cardiovascular Medicine, 2024. 14(3).
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
